Selective acting steroid's concept [5];Le concept de stéroïde à action sélective selective acting steroid's concept

Gynecologie Obstetrique et Fertilite

Volumn 28, Issue 12, 2000, Pages 931-939

  Jamin, C ^a  

^a NONE   (France)

Author keywords

Bone; Breast; Coagulation; Endometrium; Libido; Metabolism; Selective action steroids; Tibolone

Indexed keywords

STEROID; TIBOLONE;

BLOOD CLOTTING; BONE; BREAST; CLIMACTERIUM; DRUG ABSORPTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERANCE; DYSPAREUNIA; HUMAN; LIBIDO; LIVER METABOLISM; MENOPAUSE; OSTEOPOROSIS; REVIEW; SEXUALITY; STEROID THERAPY; THROMBOSIS;

EID: 0034528530     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Tibolone in the treatment of psychosomatic symptoms in menopause
2. Microscopic evaluation of the effect of hormone replacement therapy on the endometrium in women who bleed
3. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women
4. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women
5. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: A comparison
6. A comparative study of an estradiol-releasing vaginal ring versus tibolone in postmenopausal women: A transvaginal color doppler study
7. Effect of tibolone on glucose and lipid metabolism in postmenopausal women
8. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apoliporoteins al and b
9. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
10. Effect of tibolone (Org OD14) and Its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells
11. Effects of tibolone on the breast
12. The effects of gonadotrophin-releasing hormone agonists on lilac crest cancellous bone structure in women with endometriosis
13. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14
14. Treatment of climacteric complaints with Org OD 14: A comparative study with oestradiol valerate and placebo
15. Risk of venous thromboembolism in users of hormone replacement therapy
16. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT
17. Tibolone prevents ovariectomy-induced bone loss and reduces bone resorption via the estradiol receptor [abstract 332]
18. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints
19. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
20. Mammographic changes in women receiving tibolone therapy
21. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen
22. Effects of tibolone on lipoprotein (a) and HDL subfractions
23. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis
24. Short term blood pressure and metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes
25. Org OD 14 and the endometrium
26. Effect of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal
27. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis
28. Cause of vaginal bleeding in postmeno pausal women taking tibolone
29. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells
30. Effect of tibolone on postmenopausal women with myomas
31. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone
32. Microscopic findings of the nail-fold capillaries - Dependence on menopausal status and hormone replacement therapy
33. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women
34. A doubleblind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
35. Tibolone: Influence on markers of cardiovascular disease
36. Insulin-like growth factor (IGF)-I levels in postmenopausal women recei ving tibolone
37. Tibolone: Vaginal bleeding and the specific endometrial response in postmenopausal women
38. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells
39. Placebocontrolled cross-over study of effects of Org OD 14 in menopausal women
40. Effect of tibolone in breast tumor models [abstract]
41. The effect of add-back treatment with (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapepty)
42. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone
43. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina
44. Prevention of post oophorectomy bone loss with tibolone
45. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy
46. Climacteric symptoms, gonadotrophins, sex steroids, and binding proteins with conjugated equine estrogen progestin and tibolone over two years
47. High resolution ultrasound assessment of the carotid artery: Its relevance in postmenopausal women and the effects of tibolone on carotied artery ultrastructure
48. The effect of tibolone on plasma homocysteine levels in asymptomatic postmenopausal women [abstract]
49. Long term effects of tibolone on the genital tract in postmenopausal women
50. Effect on sexual life - A comparison between tibolone and a continous estradiol-norethisterone acetate regimen
51. Changes in sex behaviour after menopause: Effects of tibolone
52. Long-term administration of tibolone plus gonadotropin releasing hormone agonist for the treatment of uterine leiomyomas: Effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles
53. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata
54. Control of estrone sulfatase activity in human breast cancer cells: Effect of tibolone and its metabolites
55. Comparative effects on bone mineral density of tibolone transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women
56. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diatetes mellitus
57. The effect of tibolone on cardiac flow in postmenopausal women with non-insulin dependant diabetes mellitus
58. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women
59. A Multicentre Prospective study of the effects of tibolone on the endometrium of post-menopausal women
60. Changes in lipidic and hemosttic parameters induced by tibolone treatment
61. Psychological effects of hormone replacement therapy: A comparison of tibolone and a sequential estrogen therapy
62. Tibolone and climacteric symptoms
63. Effect of tibolone on postmenopausal bone loss
64. A study of the effect of tibolone on the vaginal in postmenopausal women
65. The incidence of vaginal bleeding with tibolone treatment
66. Weight gain in women on HRT
67. Effects of tibolone on serum concentrations of liporotein (a) in postmenopausal women
68. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures
69. Human endome trial 3 beta-hydroxysteroid dehydrogenase/Isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14)
70. Comparison of the effects of tibolone and hormone replacement therapy on echocardiographic basic cardiac functions in postmenopausal women: A randomized placebo controlled study
71. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserilin treatment in patients with endometriosis
72. Clinical profile of Org OD 14
73. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints
74. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women
75. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy
76. The effect of the synthetic steroid Org OD 14 on fibrinolysis and blood lipids in postmenopausal women
77. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovadectomized rabbits